SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Index Ventures: "We denounce the proposed reforms in Israel that foster discrimination and threaten democracy"

Dell acquires Israeli startup Cloudify for up to $100 million

OpenWeb acquires audience management platform Jeeng for $100 million

Technion to invest $20 million in new Sustainable Protein Research Center

Buzz

Most popular

Daily

Weekly

1

Israeli Fintech startups to watch out for in 2023

2

Qualcomm set to cut dozens of jobs in Israel in new round of layoffs

3

Papaya Global CEO: “We will withdraw all of the company's funds from Israel due to the emerging judicial reform”

4

McKinsey acquiring Israeli AI platform Iguazio for $50 million

5

Remote HR startup Deel hits $295 million in ARR, $12 billion valuation

Biopharma

6 stories about Biopharma

Rivki Stern Short Wave

Biopharma company Short Wave partnering in clinical trial for eating disorders with Sheba Fund

The trial will study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa

ד"ר גילי הרט מנכ"לית ספלייסנס

SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF

13.05.21|Meir Orbach

The Israeli startup was founded by Prof. Batsheva Kerem, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research

רום לקריץ מושיק כהן קוטנר ו ניב בחנוף אומניקס מדיקל Omnix Medical

Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria

26.01.21|Meir Orbach

The novel agents developed by Omnix are designed as an alternative to classical antibiotics

נאסד"ק וול סטריט

Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering

Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland

נאסד"ק וול סטריט

Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq

24.07.18|Lilach Baumer

The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market

RedHill's Public Offering Spooks Investors, Sends Stock Down

09.11.17|Dror Reich

The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close